Peptide Encyclopedia / PNC-27
EncyclopediaPNC-27 is a chimeric peptide joining part of the p53 HDM-2-binding domain to a membrane-penetrating sequence, proposed to punch pores in cancer-cell membranes while sparing normal cells. The evidence is in-vitro and animal work from a single group, and it stays a gray-market research chemical. Educational only, not medical advice.
| Category | Other |
| Regulatory status | Not FDA-approved; research chemical / gray-market in the US. |
A chimeric peptide combining residues ~12-26 of the p53 HDM-2-binding domain with a membrane-residency/penetrating leader sequence. It is proposed to bind HDM-2 displayed in the plasma membrane of cancer cells (but reportedly not normal cells), forming transmembrane pores that cause membranolysis/necrosis selectively in cancer cells.
uncertain / limited human pharmacokinetic data; no validated human PK exists.
Not FDA-approved; research chemical / gray-market in the US. Not an approved drug anywhere; remains an experimental anticancer peptide candidate. Not on FDA compounding lists.
No established human safety data. A membrane-lytic mechanism raises theoretical concerns for off-target cytotoxicity and infusion/lysis-related effects; characterization is limited to lab/animal studies. Gray-market purity unverified. Should not be self-administered.
Preclinical. Peer-reviewed in-vitro and animal studies (largely from a single Mount Sinai-affiliated group and collaborators) describe selective cancer-cell killing, but there are no robust human clinical trials confirming efficacy or safety.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. PNC-27 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
